ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $78,920 | +15.2% | 842,801 | +9.8% | 1.23% | +25.1% |
| Q2 2023 | $68,493 | -25.0% | 767,427 | -9.9% | 0.98% | -26.4% |
| Q1 2023 | $91,360 | -5.5% | 852,080 | +7.7% | 1.34% | -2.9% |
| Q4 2022 | $96,635 | -99.9% | 791,245 | +23.7% | 1.38% | +49.6% |
| Q3 2022 | $66,053,000 | +58.0% | 639,675 | +42.3% | 0.92% | +57.6% |
| Q2 2022 | $41,799,000 | -28.8% | 449,650 | -10.2% | 0.58% | -11.5% |
| Q1 2022 | $58,733,000 | -19.8% | 500,450 | -8.1% | 0.66% | +1.5% |
| Q4 2021 | $73,278,000 | -21.3% | 544,700 | -6.8% | 0.65% | -20.2% |
| Q3 2021 | $93,148,000 | +94.9% | 584,400 | +60.9% | 0.81% | +107.9% |
| Q2 2021 | $47,792,000 | -20.5% | 363,300 | -22.1% | 0.39% | -24.1% |
| Q1 2021 | $60,097,000 | -16.8% | 466,300 | +7.6% | 0.52% | -12.3% |
| Q4 2020 | $72,249,000 | +8.4% | 433,200 | +0.3% | 0.59% | -5.9% |
| Q3 2020 | $66,645,000 | +96.3% | 431,860 | +88.1% | 0.62% | +92.6% |
| Q2 2020 | $33,952,000 | – | 229,560 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |